<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Health Technology Assessment &amp; Market Access: A Strategic Guide | ArcaScience</title>
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700&display=swap" rel="stylesheet">
    <style>
        *, *::before, *::after { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Inter', -apple-system, BlinkMacSystemFont, sans-serif;
            color: #1a1a2e;
            line-height: 1.7;
            font-size: 11pt;
            background: #ffffff;
        }

        .page-header {
            background: linear-gradient(135deg, #2563EB 0%, #1e40af 100%);
            color: #ffffff;
            padding: 60px 60px 50px;
        }

        .page-header .logo {
            font-size: 14pt;
            font-weight: 700;
            letter-spacing: 1.5px;
            text-transform: uppercase;
            margin-bottom: 30px;
            opacity: 0.9;
        }

        .page-header h1 {
            font-size: 26pt;
            font-weight: 700;
            line-height: 1.2;
            margin-bottom: 15px;
            max-width: 700px;
        }

        .page-header .subtitle {
            font-size: 13pt;
            font-weight: 300;
            opacity: 0.9;
            max-width: 600px;
        }

        .page-header .meta {
            margin-top: 25px;
            font-size: 9pt;
            opacity: 0.75;
        }

        .content {
            max-width: 760px;
            margin: 0 auto;
            padding: 50px 60px;
        }

        h2 {
            font-size: 18pt;
            font-weight: 700;
            color: #2563EB;
            margin-top: 40px;
            margin-bottom: 15px;
            padding-bottom: 8px;
            border-bottom: 2px solid #e5e7eb;
        }

        h3 {
            font-size: 13pt;
            font-weight: 600;
            color: #1e40af;
            margin-top: 25px;
            margin-bottom: 10px;
        }

        p {
            margin-bottom: 14px;
            text-align: justify;
        }

        .executive-summary {
            background: #f0f4ff;
            border-left: 4px solid #2563EB;
            padding: 25px 30px;
            margin: 30px 0;
            border-radius: 0 8px 8px 0;
        }

        .executive-summary h2 {
            margin-top: 0;
            border-bottom: none;
            padding-bottom: 0;
        }

        ul, ol {
            margin-bottom: 14px;
            padding-left: 25px;
        }

        li {
            margin-bottom: 6px;
        }

        .callout {
            background: #f8fafc;
            border: 1px solid #e2e8f0;
            border-radius: 8px;
            padding: 20px 25px;
            margin: 20px 0;
        }

        .callout-title {
            font-weight: 600;
            color: #2563EB;
            margin-bottom: 8px;
        }

        table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            font-size: 10pt;
        }

        th {
            background: #2563EB;
            color: #ffffff;
            padding: 10px 14px;
            text-align: left;
            font-weight: 600;
        }

        td {
            padding: 10px 14px;
            border-bottom: 1px solid #e5e7eb;
            vertical-align: top;
        }

        tr:nth-child(even) td {
            background: #f8fafc;
        }

        .agency-card {
            background: #f8fafc;
            border: 1px solid #e2e8f0;
            border-radius: 10px;
            padding: 22px 26px;
            margin: 15px 0;
        }

        .agency-card h4 {
            color: #2563EB;
            font-size: 12pt;
            margin-bottom: 4px;
        }

        .agency-card .country {
            font-size: 9pt;
            color: #64748b;
            margin-bottom: 10px;
        }

        .agency-card ul {
            font-size: 10pt;
            margin-bottom: 0;
        }

        .timeline-item {
            display: flex;
            margin: 12px 0;
            padding: 14px 18px;
            background: #f0f4ff;
            border-radius: 8px;
        }

        .timeline-item .year {
            flex-shrink: 0;
            width: 70px;
            font-weight: 700;
            color: #2563EB;
            font-size: 12pt;
        }

        .timeline-item .event {
            flex: 1;
        }

        .cta-section {
            background: linear-gradient(135deg, #2563EB 0%, #1e40af 100%);
            color: #ffffff;
            padding: 35px;
            border-radius: 12px;
            margin: 40px 0 20px;
            text-align: center;
        }

        .cta-section h3 {
            color: #ffffff;
            font-size: 16pt;
            margin-bottom: 10px;
        }

        .cta-section p {
            text-align: center;
            opacity: 0.9;
        }

        .cta-section .cta-link {
            color: #ffffff;
            font-weight: 600;
            text-decoration: underline;
        }

        .page-footer {
            text-align: center;
            padding: 30px 60px;
            font-size: 8.5pt;
            color: #94a3b8;
            border-top: 1px solid #e5e7eb;
        }

        @media print {
            body { font-size: 10pt; }
            .page-header { padding: 40px; -webkit-print-color-adjust: exact; print-color-adjust: exact; }
            .content { padding: 30px 40px; }
            .cta-section { -webkit-print-color-adjust: exact; print-color-adjust: exact; }
            .executive-summary { -webkit-print-color-adjust: exact; print-color-adjust: exact; }
            .timeline-item { -webkit-print-color-adjust: exact; print-color-adjust: exact; }
            th { -webkit-print-color-adjust: exact; print-color-adjust: exact; }
            h2, h3 { page-break-after: avoid; }
            table, .callout, .agency-card { page-break-inside: avoid; }
        }
    </style>
</head>
<body>

<div class="page-header">
    <div class="logo">ArcaScience</div>
    <h1>Health Technology Assessment &amp; Market Access: A Strategic Guide</h1>
    <div class="subtitle">Navigating the evolving HTA landscape with AI-powered evidence generation and submission preparation</div>
    <div class="meta">Whitepaper | 2026 | arcascience.ai</div>
</div>

<div class="content">

    <div class="executive-summary">
        <h2>Executive Summary</h2>
        <p>
            Health Technology Assessment (HTA) has become the primary gatekeeper for market access in most developed healthcare systems. As HTA requirements become more demanding and the EU HTA Regulation creates new harmonized assessment processes, pharmaceutical companies must adapt their evidence generation strategies to meet evolving expectations. A product with strong clinical efficacy data may still face restricted reimbursement or unfavorable pricing if it fails to demonstrate value through the HTA lens.
        </p>
        <p>
            This guide provides a strategic overview of the major HTA agencies and their requirements, examines the implications of recent EU HTA regulatory changes, and describes how ArcaScience's HTA module helps pharmaceutical companies prepare compelling submissions that demonstrate clinical and economic value. From cost-effectiveness modeling to budget impact analysis and indirect treatment comparisons, the platform streamlines the evidence generation process while ensuring methodological rigor.
        </p>
    </div>

    <h2>1. HTA Landscape Overview</h2>

    <p>
        Health Technology Assessment is a systematic evaluation process that examines the clinical, economic, ethical, and social implications of healthcare technologies. While HTA methodologies vary by country, they share a common objective: to inform resource allocation decisions by assessing whether a new technology provides sufficient value to justify its cost.
    </p>
    <p>
        The global HTA landscape is complex and fragmented, with more than 60 HTA agencies worldwide, each with distinct methodological preferences, evidence requirements, and decision-making processes. Understanding the specific requirements of key agencies is essential for market access planning.
    </p>

    <div class="agency-card">
        <h4>NICE (National Institute for Health and Care Excellence)</h4>
        <div class="country">United Kingdom</div>
        <ul>
            <li><strong>Primary methodology:</strong> Cost-effectiveness analysis using Quality-Adjusted Life Years (QALYs)</li>
            <li><strong>Willingness-to-pay threshold:</strong> Typically GBP 20,000-30,000 per QALY gained; higher thresholds for end-of-life treatments and highly specialized technologies</li>
            <li><strong>Key requirements:</strong> Systematic review, economic model (typically Markov or partitioned survival), budget impact analysis, patient and clinical expert input</li>
            <li><strong>Notable features:</strong> Transparent process with published assessment reports; Patient Access Schemes; managed access agreements for uncertain evidence</li>
        </ul>
    </div>

    <div class="agency-card">
        <h4>G-BA / IQWiG (Federal Joint Committee / Institute for Quality and Efficiency in Health Care)</h4>
        <div class="country">Germany</div>
        <ul>
            <li><strong>Primary methodology:</strong> Added therapeutic benefit assessment (comparative effectiveness)</li>
            <li><strong>Benefit categories:</strong> Major, considerable, minor, non-quantifiable, no added benefit, less benefit</li>
            <li><strong>Key requirements:</strong> Dossier with direct comparison data (RCTs preferred), patient-relevant outcomes (mortality, morbidity, quality of life, adverse events)</li>
            <li><strong>Notable features:</strong> Cost-effectiveness analysis only triggered if manufacturer and sickness funds cannot agree on price; AMNOG process within 6 months of launch</li>
        </ul>
    </div>

    <div class="agency-card">
        <h4>HAS (Haute Autorit&eacute; de Sant&eacute;)</h4>
        <div class="country">France</div>
        <ul>
            <li><strong>Primary methodology:</strong> Clinical benefit (SMR) and improvement in clinical benefit (ASMR) assessments</li>
            <li><strong>Benefit levels:</strong> ASMR I (major improvement) through ASMR V (no improvement)</li>
            <li><strong>Key requirements:</strong> Comparative clinical data, public health impact assessment, target population estimate</li>
            <li><strong>Notable features:</strong> ASMR rating directly influences price negotiations; emphasis on unmet medical need and public health perspective</li>
        </ul>
    </div>

    <div class="agency-card">
        <h4>CADTH (Canadian Agency for Drugs and Technologies in Health)</h4>
        <div class="country">Canada</div>
        <ul>
            <li><strong>Primary methodology:</strong> Cost-effectiveness analysis; deliberative process including patient input</li>
            <li><strong>Key requirements:</strong> Systematic review, pharmacoeconomic evaluation, budget impact analysis, patient group input</li>
            <li><strong>Notable features:</strong> Pan-Canadian process for most drugs; separate process for oncology (pCODR); significant patient engagement</li>
        </ul>
    </div>

    <h2>2. EU HTA Regulation Changes</h2>

    <p>
        The EU HTA Regulation (Regulation 2021/2282), which begins its phased implementation starting January 2025, represents the most significant change to the European HTA landscape in decades. The regulation establishes a framework for joint clinical assessments (JCAs) at the EU level, fundamentally changing how HTA is conducted for new medicines.
    </p>

    <h3>2.1 Implementation Timeline</h3>

    <div class="timeline-item">
        <div class="year">2025</div>
        <div class="event"><strong>Phase 1:</strong> Joint clinical assessments begin for oncology medicines and Advanced Therapy Medicinal Products (ATMPs). EU-level assessment of relative clinical effectiveness; member states retain authority over pricing and reimbursement decisions.</div>
    </div>

    <div class="timeline-item">
        <div class="year">2028</div>
        <div class="event"><strong>Phase 2:</strong> Scope expands to include orphan medicinal products. Increasing experience and harmonization of assessment methodology across EU member states.</div>
    </div>

    <div class="timeline-item">
        <div class="year">2030</div>
        <div class="event"><strong>Phase 3:</strong> Full scope application to all new active substances and certain new indications. Complete implementation of EU-level joint clinical assessments.</div>
    </div>

    <h3>2.2 Implications for Pharmaceutical Companies</h3>
    <p>
        The EU HTA Regulation has several important implications:
    </p>
    <ul>
        <li><strong>Single submission, multiple uses:</strong> A single joint clinical assessment dossier will inform HTA decisions across all 27 EU member states, increasing the importance of getting the evidence package right</li>
        <li><strong>Comparator selection:</strong> The choice of comparator(s) for joint assessments must be agreed with the HTA Coordination Group, requiring early engagement and strategic planning</li>
        <li><strong>PICO framework:</strong> Population, Intervention, Comparator, and Outcome definitions will be established at EU level, potentially differing from individual member state preferences</li>
        <li><strong>Timeline alignment:</strong> Joint clinical assessments are designed to be completed around the time of marketing authorization, requiring parallel preparation of regulatory and HTA dossiers</li>
        <li><strong>Continued national assessments:</strong> While joint clinical assessments cover relative effectiveness, member states retain full authority over economic evaluations, pricing, and reimbursement decisions</li>
    </ul>

    <h2>3. Evidence Requirements by Agency</h2>

    <table>
        <thead>
            <tr>
                <th>Evidence Type</th>
                <th>NICE</th>
                <th>G-BA/IQWiG</th>
                <th>HAS</th>
                <th>EU JCA</th>
            </tr>
        </thead>
        <tbody>
            <tr>
                <td>Direct comparative RCT data</td>
                <td>Required</td>
                <td>Strongly preferred</td>
                <td>Required</td>
                <td>Required</td>
            </tr>
            <tr>
                <td>Indirect treatment comparisons</td>
                <td>Accepted (NMA)</td>
                <td>Accepted with caveats</td>
                <td>Accepted</td>
                <td>Accepted</td>
            </tr>
            <tr>
                <td>Real-world evidence</td>
                <td>Supportive</td>
                <td>Supplementary</td>
                <td>Supportive</td>
                <td>Supportive</td>
            </tr>
            <tr>
                <td>Cost-effectiveness model</td>
                <td>Required (QALY)</td>
                <td>Conditional</td>
                <td>Not primary</td>
                <td>Not included</td>
            </tr>
            <tr>
                <td>Budget impact analysis</td>
                <td>Required</td>
                <td>Not primary</td>
                <td>Required</td>
                <td>Not included</td>
            </tr>
            <tr>
                <td>Patient-reported outcomes</td>
                <td>Important</td>
                <td>Critical (QoL)</td>
                <td>Important</td>
                <td>Required</td>
            </tr>
            <tr>
                <td>Subgroup analyses</td>
                <td>Expected</td>
                <td>Required</td>
                <td>Expected</td>
                <td>Required</td>
            </tr>
        </tbody>
    </table>

    <h2>4. Cost-Effectiveness Modeling</h2>

    <p>
        Cost-effectiveness analysis (CEA) remains central to HTA submissions in many jurisdictions. ArcaScience's platform supports the development, validation, and adaptation of cost-effectiveness models:
    </p>

    <h3>4.1 Model Types</h3>
    <ul>
        <li><strong>Partitioned survival models:</strong> Most common in oncology; partition overall survival curve into pre-progression and post-progression states using trial-based Kaplan-Meier data with parametric extrapolation</li>
        <li><strong>Markov cohort models:</strong> Suitable for chronic diseases with defined health states and regular transitions; widely used in rheumatology, cardiology, and respiratory disease</li>
        <li><strong>Discrete event simulation:</strong> Appropriate for complex patient pathways with heterogeneous populations, competing risks, and individual-level variation; increasingly used for precision medicines</li>
        <li><strong>Microsimulation models:</strong> Individual patient-level models that track patients through disease progression; valuable when patient history affects future transitions</li>
    </ul>

    <h3>4.2 AI-Enhanced Modeling</h3>
    <p>
        ArcaScience's platform enhances the modeling process through:
    </p>
    <ul>
        <li>Automated parametric survival curve fitting and selection using AIC/BIC criteria with clinical plausibility assessment</li>
        <li>Machine learning-assisted extrapolation that incorporates external data sources for long-term projections</li>
        <li>Automated sensitivity analysis across all model parameters with identification of key value drivers</li>
        <li>Multi-country model adaptation with jurisdiction-specific cost and resource use inputs</li>
        <li>Scenario analysis for managed access agreements and outcomes-based contracting</li>
    </ul>

    <h2>5. Budget Impact Analysis</h2>

    <p>
        Budget impact analysis (BIA) estimates the financial consequences of adopting a new technology within a specific healthcare system. While conceptually simpler than CEA, BIA requires careful estimation of:
    </p>
    <ul>
        <li><strong>Eligible population:</strong> Epidemiological data on disease prevalence, diagnosis rates, treatment eligibility, and market share projections</li>
        <li><strong>Treatment costs:</strong> Drug acquisition costs, administration costs, monitoring requirements, and adverse event management costs</li>
        <li><strong>Displacement effects:</strong> Costs avoided from treatments that the new technology replaces, including downstream healthcare utilization changes</li>
        <li><strong>Uptake assumptions:</strong> Realistic market penetration scenarios based on clinical positioning, guidelines, and competitor landscape</li>
    </ul>
    <p>
        ArcaScience automates BIA development by integrating epidemiological databases, pricing intelligence, and market research data, enabling rapid scenario modeling across multiple markets simultaneously.
    </p>

    <h2>6. ArcaScience's HTA Module Capabilities</h2>

    <table>
        <thead>
            <tr>
                <th>Capability</th>
                <th>Description</th>
                <th>Benefit</th>
            </tr>
        </thead>
        <tbody>
            <tr>
                <td>Comparative effectiveness synthesis</td>
                <td>Automated systematic review, network meta-analysis, and indirect treatment comparisons</td>
                <td>50% faster evidence synthesis with transparent methodology documentation</td>
            </tr>
            <tr>
                <td>Economic model development</td>
                <td>Template-based model construction with AI-assisted parameterization and validation</td>
                <td>Reduced modeling time with built-in quality checks and audit trails</td>
            </tr>
            <tr>
                <td>Multi-country adaptation</td>
                <td>Automated adaptation of base-case model to country-specific healthcare contexts</td>
                <td>Parallel submission preparation for multiple markets from a single evidence base</td>
            </tr>
            <tr>
                <td>Dossier generation</td>
                <td>Automated generation of HTA submission dossiers in agency-specific formats</td>
                <td>Consistent, high-quality submissions meeting agency-specific formatting requirements</td>
            </tr>
            <tr>
                <td>Scenario planning</td>
                <td>Rapid scenario analysis for pricing, access restrictions, and managed entry agreements</td>
                <td>Data-driven commercial strategy supporting pricing and access negotiations</td>
            </tr>
            <tr>
                <td>Benefit-risk integration</td>
                <td>Direct integration of quantitative BRA results into HTA value demonstration</td>
                <td>Coherent value story from regulatory approval through market access</td>
            </tr>
        </tbody>
    </table>

    <h2>7. Preparing HTA Submissions</h2>

    <h3>7.1 Early Planning (Phase 2-3)</h3>
    <p>
        Successful HTA submissions begin with evidence planning during clinical development. Key activities include:
    </p>
    <ul>
        <li>Identify target HTA agencies and their specific evidence preferences</li>
        <li>Select comparators aligned with both regulatory and HTA requirements</li>
        <li>Design trials to capture HTA-relevant endpoints (quality of life, resource use, patient preferences)</li>
        <li>Plan for RWE generation to supplement clinical trial data</li>
        <li>Engage with HTA bodies through scientific advice processes</li>
    </ul>

    <h3>7.2 Submission Preparation</h3>
    <ul>
        <li>Develop global value dossier with core evidence package adaptable to all target markets</li>
        <li>Conduct systematic review and network meta-analysis for comparative effectiveness</li>
        <li>Build and validate economic model with jurisdiction-specific adaptations</li>
        <li>Prepare budget impact analyses for each target market</li>
        <li>Draft submission documents in agency-specific formats</li>
        <li>Develop payer engagement materials and negotiation scenarios</li>
    </ul>

    <h3>7.3 Post-Submission</h3>
    <ul>
        <li>Prepare for agency clarification questions and technical engagement meetings</li>
        <li>Conduct additional analyses as requested (subgroups, alternative comparators, scenario variations)</li>
        <li>Prepare for advisory committee or appraisal committee presentations</li>
        <li>Develop implementation plans including risk-sharing agreements if applicable</li>
        <li>Plan for resubmission or appeal if initial recommendation is unfavorable</li>
    </ul>

    <div class="cta-section">
        <h3>Accelerate Your Market Access Strategy</h3>
        <p>See how ArcaScience's HTA module can streamline your evidence generation and submission preparation.</p>
        <p style="margin-top: 15px; margin-bottom: 0;">
            <a class="cta-link" href="https://arcascience.ai/contact">Schedule a Demo</a> &nbsp;|&nbsp;
            <a class="cta-link" href="mailto:info@arcascience.ai">info@arcascience.ai</a>
        </p>
    </div>

</div>

<div class="page-footer">
    &copy; 2026 ArcaScience. All rights reserved. | arcascience.ai<br>
    This document is provided for informational purposes only. HTA requirements and regulatory landscapes are subject to change.
</div>

</body>
</html>
